Literature DB >> 15249714

Diagnosis and treatment of paraneoplastic neurological disorders.

R Voltz1, F Graus.   

Abstract

In about two thirds of cases, patients with paraneoplastic neurological disorders present to the neurologist without a known tumor. Due to the ongoing immune response, this tumor tends to stay biologically relatively benign, and therefore difficult to diagnose. In patients with a known tumor, the neurological symptoms often precede a tumor recurrence. In both scenarios, anti-neuronal antibodies are an invaluable diagnostic help to the clinician, and may be supplemented by other diagnostic tests such as MRI, CSF, and electrophysiology. Tumor therapy remains the mainstay of therapeutic options, although early immune therapy must be started in parallel. It is hoped that the recent fundamental advances in understanding the autoimmune pathology of these disorders, especially the role of cytotoxic T cells, will eventually lead to more effective treatment options. Copyright 2004 S. Karger GmbH, Freiburg

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249714     DOI: 10.1159/000077975

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  3 in total

1.  18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis.

Authors:  Peter Bannas; Christoph Weber; Thorsten Derlin; Jörg Lambert; Frank Leypoldt; Gerhard Adam; Janos Mester; Susanne Klutmann
Journal:  Eur Radiol       Date:  2009-09-30       Impact factor: 5.315

2.  Paraneoplastic Cerebellar Degeneration Associated With Ovarian Adenocarcinoma: A Case Report and Review of Literature.

Authors:  Pushpendra Nath Renjen; Dinesh Mohan Chaudhari; U S Shilpi; Dhruv Zutshi; Kamal Ahmad
Journal:  Ann Indian Acad Neurol       Date:  2018 Oct-Dec       Impact factor: 1.383

3.  Paraneoplastic neurological syndromes: severe neurological symptoms resulting from relatively benign or occult tumours-two case reports.

Authors:  M Ghadiri-Sani; Mueez Waqar; Dave Smith; Mark Doran
Journal:  Case Rep Oncol Med       Date:  2013-04-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.